摘要
小细胞肺癌(small cell lung cancer,SCLC)转化是非小细胞肺癌尤其是表皮生长因子受体(epidermal growth factor receptor,EGFR)突变患者的重要耐药机制之一。目前发现转化性SCLC具有与原发性SCLC相似的临床特征,对化疗短期有效,中位生存期仅1年左右。RB1缺失、体细胞拷贝数改变与SCLC转化有关,但发生SCLC转化的确切分子机制仍不完全清楚。转化性SCLC的治疗也面临巨大的挑战,针对SCLC的化疗方案是目前的主要治疗选择,联合治疗、局部治疗以及预防SCLC转化的策略也在探索。本文将转化性SCLC的临床特征、分子机制和治疗选择进行综述。
The transformation of non-small cell lung cancer to small cell lung cancer(SCLC)is one of the major resistant mechanisms,especially patients with epidermal growth factor receptor mutant lung adenocarcinoma.Translational SCLC has been found to have similar clinical features to primary SCLC.Chemotherapy was short-term effective for transformational SCLC,with a median survival of only about 1 year.The deletion of RB1 and the change of somatic copy number were associated with SCLC transformation.Although the molecular mechanism of SCLC transformation is still not fully understood.At the same time,the treatment of transformational SCLC also faces great challenges.Currently,chemotherapy regimens for SCLC are the main treatment options for transforming SCLC.Combination therapy,local treatment and strategies for prevention of SCLC transformatio are also being explored.This article will review research advances on the clinical features,molecular mechanism and treatment options of translational SCLC.
作者
张爽
李双
崔雅楠
程颖
Shuang ZHANG;Shuang LI;Yanan CUI;Ying CHENG(Department of Thoracic Oncology,Jilin Cancer Hospital,Changchun 130000,China)
出处
《中国肺癌杂志》
CAS
CSCD
北大核心
2021年第10期729-733,共5页
Chinese Journal of Lung Cancer
关键词
肺肿瘤
转化
机制
治疗
Lung neoplasms
Transformation
Mechanism
Therapy
